EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of homologous recombination repair/BReast CAncer ( BRCA ) gene alterations on survival in a real‐world setting of metastatic prostate cancer

Mike Wenzel iD, Benedikt Hoeh, Florestan Koll, Clara Humke, Anne Fassl, Henning Reis, Peter Wild, Thomas Steuber, Markus Graefen, Derya Tilki iD, Miriam Traumann, Severine Banek und 2 weitere

BJU International · 2025

DOI: 10.1111/bju.16462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Mike Wenzel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany. Hauptthemen laut MEDLINE: Recombinational DNA Repair, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate alterations of homologous recombination repair (HRR) and especially BReast CAncer 1/2 ( BRCA 1/2) gene on overall survival (OS). Moreover, to explore the effect of inhibition of poly(ADP‐ribose)‐polymerase (PARPi) as systemic therapy for metastatic castration‐resistant prostate cancer (mCRPC). Patients and methods Of all HRR‐screened patients with metastatic prostate cancer, baseline characteristics were sampled. Kaplan–Meier estimates and multivariable Cox regression models predicted the effect of HRR/ BRCA 1/2 alterations on OS.

Results

Of 196 eligible patients, 61 (31%) harboured any HRR and 40 (20%) BRCA 1/2 alterations. Of HRR alterations, 40 (66%) vs six (10%) vs five (8.2%) vs four (6.6%) vs two (3.3%) vs four (6.6%) were BRCA 1/2 vs Ataxia‐telangiectasia mutated kinase ( ATM ) vs checkpoint kinase 2 ( CHEK 2) vs cyclin‐dependent kinase 12 ( CDK 12) vs Fanconi anaemia complementation Group A ( FANCA ) vs positive for other mutations. Of these, 30% received a PARPi. OS differed significantly between HRR‐positive vs ‐negative patients. Specifically in hormone‐sensitive prostate cancer, the median OS was 63 (HRR positive) vs 57 ( BRCA 1/2 positive) vs 113 months (HRR negative) ( P ≤ 0.01). In mCRPC, OS was 42 (HRR positive) vs 41 ( BRCA 1/2 positive) vs 70 months (HRR negative) ( P ≤ 0.01). HRR and BRCA 1/2 alterations were associated with worse OS after multivariable adjustment. Finally, patients with mCRPC with BRCA 1/2 mutation treated without PARPi harboured worse OS than patients with BRCA 1/2 mutation and PARPi therapy (median OS: 33 vs 48 months, P < 0.03).

Conclusion

Incidence of HRR alteration in a clinical real‐world setting is high when using blood‐ and tissue‐based tests. Patients with HRR/ BRCA alterations have worse outcomes resulting in significant OS differences between HRR/ BRCA ‐positive patients with mCRPC with and without PARPi usage vs HRR/ BRCA ‐negative patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinational DNA RepairPoly(ADP-ribose) Polymerase InhibitorsHumansMaleAgedMiddle AgedProstatic Neoplasms, Castration-ResistantBRCA1 ProteinBRCA2 ProteinCyclin-Dependent KinasesAtaxia Telangiectasia Mutated ProteinsGenes, BRCA1MutationGenes, BRCA2Aged, 80 and overProstatic NeoplasmsCheckpoint Kinase 2

Stichwörter der Autor:innen

BReast CAncer (BRCA) genemetastatic hormone‐sensitive prostate cancermetastatic prostate cancermutation

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinBRCA2 ProteinCDK12 protein, humanATM protein, humanCyclin-Dependent KinasesBRCA2 protein, humanAtaxia Telangiectasia Mutated ProteinsBRCA1 protein, humanCHEK2 protein, human

Autor:innen und Institutionen

  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
  • Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
  • Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Urology, Koc University Hospital, Istanbul, Turkey.

ORCID-Profile: Mike Wenzel, Derya Tilki

Zitieren

APA

Wenzel, M., Hoeh, B., Koll, F., Humke, C., Fassl, A., Reis, H., Wild, P., Steuber, T., Graefen, M., Tilki, D., Traumann, M., Banek, S., Chun, F. K. H., & Mandel, P. (2025). Impact of homologous recombination repair/BReast CAncer ( BRCA ) gene alterations on survival in a real‐world setting of metastatic prostate cancer. BJU International. https://doi.org/10.1111/bju.16462

Vancouver

Wenzel M, Hoeh B, Koll F, Humke C, Fassl A, Reis H, et al. Impact of homologous recombination repair/BReast CAncer ( BRCA ) gene alterations on survival in a real‐world setting of metastatic prostate cancer. BJU International. 2025. doi:10.1111/bju.16462

BibTeX
@article{Wenzel2025,
  author = {Wenzel, Mike and Hoeh, Benedikt and Koll, Florestan and Humke, Clara and Fassl, Anne and Reis, Henning and Wild, Peter and Steuber, Thomas and Graefen, Markus and Tilki, Derya and Traumann, Miriam and Banek, Severine and Chun, Felix K H and Mandel, Philipp},
  title = {Impact of homologous recombination repair/BReast CAncer ( BRCA ) gene alterations on survival in a real‐world setting of metastatic prostate cancer},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16462}
}
Kostenlos starten →